AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$ACOG

Wills Robert James purchased $96K of ACOG

Wills Robert James purchased 10,000 shares of Alpha Cognition Inc. (ACOG) at $9.62 on 2026-08-21.

Original reporting
SEC EDGAR · Wills Robert James
Published Aug 24, 2026, 6:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ACOG
Neutral
medium confidence
Mentioned
$ACOG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The director's purchase adds a modest amount to his holdings, offering limited insight into company prospects.

02

Market read

A small insider purchase with limited trading relevance.

03

What to watch

No disclosed strategic initiatives or material news accompany the transaction.

Relevance 4/10Novelty 4/10Timing: filed today

Background

Form 4 filings provide the first public disclosure of insider trades.

Company-level read

Ticker impact

$ACOGNeutralMedium confidence
Context

Director Wills Robert James purchased 10,000 shares of Alpha Cognition Inc. for $96,200, increasing his stake to 32,241 shares.

Expected impact

Minimal short‑term impact; price likely unchanged.

Evidence & confidence

The purchase is under $100k and represents a modest increase in holdings, typical for routine insider activity.

Market effects

Sector

None significant; insider activity does not affect sector outlook.

Regional

None; company is US‑listed with limited market footprint.

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • company
    Alpha Cognition Inc.

    Issuer of the Form 4 filing.

  • person
    Wills Robert James

    Director of Alpha Cognition Inc. who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min